Citation: S. Irfan et al., COMPARISON BETWEEN NASOLACRIMAL SYRINGING PROBING, MACRODACRYOCYSTOGRAPHY AND SURGICAL FINDINGS IN THE MANAGEMENT OF EPIPHORA/, Eye, 12, 1998, pp. 197-202
Authors:
DIGGORY P
CASSELSBROWN A
VAIL A
HILLMAN JS
Citation: P. Diggory et al., RANDOMIZED, CONTROLLED TRIAL OF SPIROMETRIC CHANGES IN ELDERLY PEOPLERECEIVING TIMOLOL OR BETAXOLOL AS INITIAL TREATMENT FOR GLAUCOMA, British journal of ophthalmology, 82(2), 1998, pp. 146-149
Authors:
COUSENS SN
CASSELSBROWN A
MURDOCH I
BABALOLA OE
JATAU D
ALEXANDER NDE
EVANS JE
DANBOYI P
ABIOSE A
JONES BR
Citation: Sn. Cousens et al., IMPACT OF ANNUAL DOSING WITH IVERMECTIN ON PROGRESSION OF ONCHOCERCALVISUAL-FIELD LOSS, Bulletin of the World Health Organization, 75(3), 1997, pp. 229-236
Citation: P. Diggory et al., TOPICAL BETA-BLOCKADE WITH INTRINSIC SYMPATHOMIMETIC ACTIVITY OFFERS NO ADVANTAGE FOR THE RESPIRATORY AND CARDIOVASCULAR FUNCTION OF ELDERLY PEOPLE, Age and ageing, 25(6), 1996, pp. 424-428
Citation: A. Casselsbrown et al., TIMOLOL OR BETAXOLOL FOR ELDERLY NEW GLAUCOMA PATIENTS, Investigative ophthalmology & visual science, 36(4), 1995, pp. 737-737
Authors:
DIGGORY P
CASSELSBROWN A
VAIL A
ABBEY LM
HILLMAN JS
Citation: P. Diggory et al., AVOIDING UNSUSPECTED RESPIRATORY SIDE-EFFECTS OF TOPICAL TIMOLOL WITHCARDIOSELECTIVE OR SYMPATHOMIMETIC AGENTS, Lancet, 345(8965), 1995, pp. 1604-1606
Authors:
RAITHEL E
WU JX
JONES BR
ADENIYI B
CASSELSBROWN A
MAHMOOD AO
ABIOSE A
Citation: E. Raithel et al., RISK-FACTORS FOR MOTION SENSITIVITY LOSS IN COMMUNITIES WITH MESOENDEMIC SAVANNA ONCHOCERCIASIS, Investigative ophthalmology & visual science, 35(4), 1994, pp. 1921-1921
Authors:
CASSELSBROWN A
MINFORD AMB
CHATFIELD SL
BRADBURY JA
Citation: A. Casselsbrown et al., OPHTHALMIC MANIFESTATIONS OF NEONATAL PROTEIN-C DEFICIENCY, British journal of ophthalmology, 78(6), 1994, pp. 486-487